The Centre of Molecular Inflammation Research (CEMIR) was established on 10. June 2013 as a Centre of Excellence appointed by the Research Council of Norway. The vision of CEMIR is to lay the foundation for identifying new therapeutic targets and developing new diagnostic tools for inflammatory diseases through an integrated 10-year programme of research and research training in molecular innate immune responses.


Inflammation is a host response that is triggered by infection and tissue injury. A controlled inflammatory response is needed to fight infections and to heal wounds, but it can become detrimental if it is dysregulated as seen in chronic inflammatory disorders like cardiovascular disease, diabetes, Alzheimer's disease, inflammatory bowel disease, obesity, cancer, and others. Drawing on major recent advances in the field of innate immunity and cell biology, CEMIR's research programme will detail the molecular and cell biological principles for initiation and regulation of inflammatory responses through the use of basic research, in vitro- and in vivo models and unique biobanks. The localisation of CEMIR in an integrated University hospital environment will facilitate translational research on human disease.


CEMIR's management consists of Director Terje Espevik, Co-Director Trude Helen Flo and Head of Administration Kari Håland


Science Advisory Board (SAB):

  • Dr. Alan Aderem,  Seattle Biomedical Research Institute, USA
  • Dr. Douglas Golenbock, University of Massachusetts Medical School, USA
  • Dr. Gøran Hansson, Karolinska Institutet, Sverige
  • Dr. Lynda Stuart, Massachusetts General Hospital, USA
  • Dr. Stefanie Vogel, University of Maryland Medical Center (UMMC), USA

Host institution

CEMIR is hosted by the Faculty of Medicine at the Norwegian University of Science and Technology (NTNU). All CEMIR activities are located in Kunnskapssenteret at St. Olavs hospital in Trondheim, Norway.


Contact CEMIR

Knowledge Centre


Annual Reports